Daher Saleh, Massarwa Muhammad, Benson Ariel A, Khoury Tawfik
Gastroenterology and Liver Units, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
J Clin Transl Hepatol. 2018 Mar 28;6(1):69-78. doi: 10.14218/JCTH.2017.00031. Epub 2017 Dec 17.
Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related mortality. The principal treatment is surgical resection or liver transplantation, depending on whether the patient is a suitable transplant candidate. However, in most patients with HCC the diagnosis is often late, thereby excluding the patients from definitive surgical resection. Medical treatment includes sorafenib, which is the most commonly used systemic therapy; although, it has been shown to only minimally impact patient survival by several months. Chemotherapy and radiotherapy are generally ineffective. Due to the poor prognosis of patients with HCC, newer treatments are needed with several being in development, either in pre-clinical or clinical studies. In this review article, we provide an update on the current and future medical and surgical management of HCC.
肝细胞癌(HCC)是癌症相关死亡的主要原因之一。主要治疗方法是手术切除或肝移植,具体取决于患者是否适合作为移植候选者。然而,大多数HCC患者确诊时往往已处于晚期,从而无法进行确定性手术切除。药物治疗包括索拉非尼,这是最常用的全身治疗药物;尽管如此,它仅能将患者生存期延长几个月。化疗和放疗通常无效。由于HCC患者预后较差,需要开发几种新的治疗方法,目前一些治疗方法正处于临床前或临床研究阶段。在这篇综述文章中,我们提供了HCC当前及未来药物和手术治疗的最新进展。